HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda
HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda Drug Target Will Advance into Takeda's Discovery Portfolio as Part of Ongoing Collaboration News provided by Share this article Share this article CHARLOTTESVILLE, Va., Dec. 10, 2020 /PRNewswire/ -- HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited ("Takeda") to advance its first nonalcoholic steatohepatitis (NASH) target into Ta...
Source: prnewswire.com